IRICoR is very pleased to announce the appointmentas of June 2, 2022 of Claude Larose, as Vice-President, Business Development and new member of IRICoR’s Management team. In this role, Mr. Larose will be primarily responsible for establishing links and concluding agreements with entities outside IRICoR, both in the public and private sectors, with a view to exit events for projects in the portfolio.
Mr. Larose joins the IRICoR team with more than 25 years of experience in the life sciences industry, divided between research and development, sales and marketing, business development and intellectual property licensing.
Before joining IRICoR, Claude worked in the private sector, where he concluded multiple national and international transactions, collaborative research and IP licensing agreements first at Quantum Biotechnologies then at Theratechnologies. Then in 2013, he was a key player at the National Research Council (NRC) in developing the overall business development, licensing and intellectual property management strategies for the Medical Devices Research Center.
He holds a master’s degree (MSc. Microbiology and immunology) from the University of Montreal. Claude has been a member of the Canadian Healthcare Licensing Association since 2004, serving on its Board of Directors from 2007 to 2017 and serving as its President from 2013 for a two-year term.